Provided by Tiger Trade Technology Pte. Ltd.

Celldex Therapeutics

40.57
+0.19000.47%
Post-market: 40.570.00000.00%16:20 EDT
Volume:416.89K
Turnover:16.90M
Market Cap:3.18B
PE:-9.35
High:40.98
Open:40.16
Low:39.53
Close:40.38
52wk High:45.14
52wk Low:21.34
Shares:78.49M
Float Shares:73.02M
Volume Ratio:0.43
T/O Rate:0.57%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.3401
EPS(LYR):-3.9000
ROE:-43.88%
ROA:-27.62%
PB:4.46
PE(LYR):-10.40

Loading ...

Celldex Therapeutics Inc : Morgan Stanley Cuts Target Price to $40.00 from $44.00

THOMSON REUTERS
·
Jul 22

Analysts Offer Insights on Healthcare Companies: Celldex (CLDX), Bristol-Myers Squibb (BMY) and Peptidream (OtherPPTDF)

TIPRANKS
·
Jul 22

Celldex Therapeutics Inc : Leerink Partners Cuts Target Price to $70 from $78

THOMSON REUTERS
·
Jul 22

Morgan Stanley Adjusts PT on Celldex Therapeutics to $40 From $44, Maintains Overweight Rating

MT Newswires Live
·
Jul 22

U.s. Research Roundup-danaher, Gm, Msci

Reuters
·
Jul 22

Celldex Shares Fall After it Drops Skin Disease Drug Study

Reuters
·
Jul 22

Celldex to End Phase 2 Study for Skin-disease Treatment

Dow Jones
·
Jul 22

Celldex reports barzolvolimab study did not meet primary, secondary endpoints

TIPRANKS
·
Jul 22

Celldex Posts Press Release on Phase 2 Barzolvolimab Results in Prurigo Nodularis

Reuters
·
Jul 22

Celldex Therapeutics - Profound Systemic Mast Cell Depletion Observed in Phase 2 Study

THOMSON REUTERS
·
Jul 22

Celldex Therapeutics Inc: Favorable Safety Profile Consistent with Prior Studies, Including with New 450mg Loading Dose and up to 300mgq4w Regimen

THOMSON REUTERS
·
Jul 22

Celldex Reports Results from Phase 2 Study of Barzolvolimab in Prurigo Nodularis

THOMSON REUTERS
·
Jul 22

Celldex Therapeutics - Phase 3 Csu Topline Data Expected Sept/oct 2026; Phase 3 Sd and Coldu Enrollment on Track

THOMSON REUTERS
·
Jul 22

Celldex Therapeutics is Maintained at Buy by Guggenheim

Dow Jones
·
Jul 20

Celldex price target raised to $100 from $90 at Guggenheim

TIPRANKS
·
Jul 20

Celldex Initiates Search for New CFO Ahead of Martin's Retirement

Dow Jones
·
Jul 16

Celldex CFO Sam Martin to Retire in 2027, Stays Through March 2027 Transition

Reuters
·
Jul 16

Celldex Announces Planned Transition of Chief Financial Officer

THOMSON REUTERS
·
Jul 16

Celldex Therapeutics - Celldx CFO SAM Martin Plans to Retire in 2027

THOMSON REUTERS
·
Jul 16

Celldex Therapeutics (CLDX) Is Up 8.8% After Broad Russell Growth Index Additions Has The Bull Case Changed?

Simply Wall St.
·
Jul 06